Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review
Publish Year: 1403
نوع سند: مقاله ژورنالی
زبان: English
View: 53
This Paper With 9 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_HPM-13-1_006
تاریخ نمایه سازی: 17 مرداد 1403
Abstract:
Background There is a lack of guidance on approaches to formulary management and funding for high-cost drugs and therapeutics by individual healthcare institutions. The objective of this review was to assess institutional approaches to resource allocation for such therapeutics, with a particular focus on paediatric and rare disease populations. Methods A search of Embase and MEDLINE was conducted for studies relevant to decision-making for off-formulary, high-cost drugs and therapeutics. Abstracts were evaluated for inclusion based on the Simple Multiple-Attribute Rating Techniques (SMART) criteria. A framework of ۳۰ topics across ۴ categories was used to guide data extraction and was based on findings from the initial abstract review and previous health technology assessment (HTA) publications. Reflexive thematic analysis was conducted using QSR NVivo ۱۲ software. Results A total of ۱۶۸ studies were included for analysis. Only ۴ (۲%) focused on paediatrics, while ۲۱ (۱۲%) centred on adults and the remainder (۸۵%) did not specify. Thirty-two (۱۹%) studies discussed the importance of high-cost therapeutics and ۳۴ (۲۳%) focused on rare/orphan drugs. Five themes were identified as being relevant to institutional decision-making for high-cost therapeutics: institutional strategy, substantive criteria, procedural considerations, guiding principles and frameworks, and operational activities. Each of these themes encompassed several sub-themes and was complemented by a sixth category specific to paediatrics and rare diseases. Conclusion The rising cost of novel drugs and therapeutics underscores the need for robust, evidence-based, and ethically defensible decision-making processes for health technology funding, particularly at the hospital level. Our study highlights practices and themes to aid decision-makers in thinking critically about institutional, substantive, procedural, and operational considerations in support of legitimate decisions about institutional funding of high-cost drugs and therapeutics, as well as opportunities and challenges that exist for paediatric and rare disease populations.
Keywords:
Authors
Daniel E. Wang
Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Maram Hassanein
Department of Bioethics, The Hospital for Sick Children, Toronto, ON, Canada
Yasmeen Razvi
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
Randi Zlotnik Shaul
Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Avram Denburg
Department of Paediatrics, University of Toronto, Toronto, ON, Canada